Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial. - Wikidata - awgldk - TriplyDB

Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial.

Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial.

http://www.wikidata.org/entity/Q34948322

about

New trends in resuscitation Exploring ethical conflicts in emergency trauma research: the COMBAT (Control of Major Bleeding after Trauma) study experience Shock index and prediction of traumatic hemorrhagic shock 28-day mortality: data from the DCLHb resuscitation clinical trials.Endothelial dysfunction enhances vasoconstriction due to scavenging of nitric oxide by a hemoglobin-based oxygen carrier.Synthesis, biophysical properties and pharmacokinetics of ultrahigh molecular weight tense and relaxed state polymerized bovine hemoglobins Anemia in critical illness: insights into etiology, consequences, and management The acute management of trauma hemorrhage: a systematic review of randomized controlled trials Exception from informed consent for emergency research: consulting the trauma community.Modulation of syndecan-1 shedding after hemorrhagic shock and resuscitation.Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: design, rationale and implementation A principal component analysis of postinjury viscoelastic assays: clotting factor depletion versus fibrinolysis The use of the Revised Trauma Score as an entry criterion in traumatic hemorrhagic shock studies: data from the DCLHb clinical trials.Revisiting early postinjury mortality: are they bleeding because they are dying or dying because they are bleeding?Advances in resuscitation strategies Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document".Biophysical properties and oxygenation potential of high-molecular-weight glutaraldehyde-polymerized human hemoglobins maintained in the tense and relaxed quaternary states.A novel nanobiotherapeutic poly-[hemoglobin-superoxide dismutase-catalase-carbonic anhydrase] with no cardiac toxicity for the resuscitation of a rat model with 90 minutes of sustained severe hemorrhagic shock with loss of 2/3 blood volume.Viscoelastic clot strength predicts coagulation-related mortality within 15 minutes Coagulation abnormalities in the trauma patient: the role of point-of-care thromboelastography.Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial.Early platelet dysfunction: an unrecognized role in the acute coagulopathy of trauma.Comparative In Vivo Effects of Hemoglobin-Based Oxygen Carriers (HBOC) with Varying Prooxidant and Physiological Reactivity The immunological properties of stroma-free polyhemolysate containing catalase and superoxide dismutase activities prepared by polymerized bovine stroma-free hemolysate.Examining and mitigating acellular hemoglobin vasoactivity.Blood substitutes: evolution from noncarrying to oxygen- and gas-carrying fluids.Refining the Enrolment Process in Emergency Medicine Research.The USA Multicenter Prehosptial Hemoglobin-based Oxygen Carrier Resuscitation Trial: scientific rationale, study design, and results Fluid resuscitation: past, present, and the future Anemia and red blood cell transfusion in neurocritical care.Nanobiotechnology for hemoglobin-based blood substitutes.Plasma first in the field for postinjury hemorrhagic shock.Blood replacement with nanobiotechnologically engineered hemoglobin and hemoglobin nanocapsules.Anemia in cancer.The contemporary role of blood products and components used in trauma resuscitation.Red Blood Cell Transfusion and Transfusion Alternatives in Traumatic Brain Injury.From artificial red blood cells, oxygen carriers, and oxygen therapeutics to artificial cells, nanomedicine, and beyond.Haemoglobin-based oxygen carriers: indications and future applications.Red blood cell replacement, or nanobiotherapeutics with enhanced red blood cell functions?The role of NIGMS P50 sponsored team science in our understanding of multiple organ failure.A new model of severe hemorrhagic shock in rats.

P2860

Q24599047-489D6E54-5C82-497C-B3F7-4DE35EA2BD16 Q27303495-3AEA533B-DC4A-44A8-AF41-C256DCE188F1 Q30876915-158FCD03-D05D-4EC4-A772-D429F57431D5 Q33692944-95C745B5-19CC-4F58-BAE6-7C3BC3C11DD4 Q33721951-78F88B8A-CE58-4FCB-B22C-040BA10A447C Q33738712-D2733E88-553D-4001-855B-09A3178DE501 Q33842873-709CEC0F-8878-4C78-9D2B-0DF996ADF886 Q33950561-12C47A6A-F804-4D0A-B8E7-22B7CF460494 Q34008848-7CEF1E34-6E40-483A-9C7C-3E17F44B49D6 Q34064066-9BED920E-04F2-491C-83A6-DC12320A7D30 Q34115729-B0439E34-6DF1-4749-AE46-D005764DBC32 Q34354806-844A2EA9-0FF8-4100-9984-6525042FE5D1 Q34372103-862C98CB-86D9-4F00-AB9B-BB9B7113DE39 Q34494272-AE1EC37D-817D-4E34-8A7E-782DEC1E2CCB Q34654443-F9FE92CF-435B-42A1-B9DA-619E1ED4B95D Q34715341-AEC6066B-693D-4668-BB1A-102FB5157AFC Q34720661-B32CAF0B-4F31-43CA-91E8-674F98B29167 Q35192620-D733ED27-0889-4C0C-BA25-FCDD3CC5830D Q35204283-FFAE749B-98BC-450F-82FE-D846276B508D Q35219638-CF2D18C3-3777-40EF-BABB-18AE060DED89 Q35948091-E9BD3613-492C-4219-8810-1D1985FC993B Q35995001-B4061D9C-7394-4764-8153-AA27306E3F0C Q36456443-7552E72D-428E-4BC1-BE23-032A1B63DB9C Q36801603-4ABA91A0-CE96-4EDD-A036-42E4122D3F8A Q36990411-4F30BBDB-E489-4312-A953-9FCDD678C815 Q37155702-5ABD8234-42D0-4C23-AAE8-0F749CD45DD1 Q37172555-0C37DCAF-73D4-4649-9306-416D50DA0281 Q37184153-C5CAE8C5-735E-4CA1-9691-ACAD4804C136 Q37279874-996BCA06-F021-47A8-98B3-583926DA69DF Q37430680-8560D513-E87B-44A1-9A78-0D8F7183B927 Q37732197-D6DB52C7-0FC3-417A-93F2-ADCAA70BB1C0 Q37766560-E86F3D36-AA2A-43BD-B04A-D59C8D490849 Q37799923-589EB63E-A01F-4EEF-95DA-41553639E0B6 Q37812157-76C3EC05-8B78-4E87-B682-9912D14FBBC4 Q37982325-4D961DB9-BC15-4396-A2AA-20ED24F6D41B Q37992678-DAD9F212-695F-40A8-9EC4-1F5626FC2F12 Q38351787-F5368054-FDCD-48CE-B526-7B5616B2E34D Q38533820-71D44A59-1BFC-4985-B9D6-D78A67896958 Q38679752-8358B6D2-7A1C-42CE-96EE-BB6A541AC0E7 Q38700721-B9736D0D-D257-40A6-8BA1-9CC19F60A6D3

P2860

Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: the USA multicenter trial.

http://www.wikidata.org/entity/Q34948322

description

2008 nî lūn-bûn

@nan

2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Human polymerized hemoglobin f ...... le: the USA multicenter trial.

@ast

Human polymerized hemoglobin f ...... le: the USA multicenter trial.

@en

Human polymerized hemoglobin f ...... le: the USA multicenter trial.

@nl

type

label

Human polymerized hemoglobin f ...... le: the USA multicenter trial.

@ast

Human polymerized hemoglobin f ...... le: the USA multicenter trial.

@en

Human polymerized hemoglobin f ...... le: the USA multicenter trial.

@nl

prefLabel

Human polymerized hemoglobin f ...... le: the USA multicenter trial.

@ast

Human polymerized hemoglobin f ...... le: the USA multicenter trial.

@en

Human polymerized hemoglobin f ...... le: the USA multicenter trial.

@nl

P1433

Q34948322-01A1AE08-8DFD-4A39-B545-AB6CE1D814CD

P1476

Q34948322-33C736D6-F408-4D94-95FB-F6CCD3FCC5A5

P2093

Q34948322-250D4DA8-4F35-482D-9322-35F2FD1C3BF9

Q34948322-2ADCFDE3-F5D5-4138-BC4B-499E72B2B931

Q34948322-3468D686-8E9F-47E3-81FA-0B5D1A91426B

Q34948322-4911D513-4704-46F5-800B-6C9850E6A09F

Q34948322-503BD067-66CA-4EB9-A0B8-73E7DF6A5EAC

Q34948322-51768558-8B1D-4F7F-839C-BDCF8620862E

Q34948322-5AB72AC1-EB06-4D44-8204-D77BC12B16D4

Q34948322-628658B7-2872-4848-9DE7-2440BA903719

Q34948322-7024ECD6-70F7-44B6-A2A8-C10E4261480D

Q34948322-8B48790A-827F-4769-B653-320B52C4DE2C

P304

Q34948322-81D100BD-7201-4F30-B144-DC7DC943335E

P31

Q34948322-AD1625C4-2464-4EC7-B36D-10AC7359898C

P356

Q34948322-F24A27CB-A607-4C2E-88F3-268F49AD534B

P433

Q34948322-7EC275A5-F5EC-42AB-AC75-A9DF0CF56611

P478

Q34948322-5346A8A5-46BE-4B75-9FE8-DE8FAFE97A5C

P50

Q34948322-B37D90BF-9C63-4FF2-8187-458DC5886262

P577

Q34948322-D0AD2863-116B-4D4E-86BF-F4547DD1CC58

P5875

Q34948322-3781EB05-C758-42AC-B67E-775C8083D531

P698

Q34948322-2BA84DBE-AB29-4D61-83DF-33EA41C73638

P921

Q34948322-847F4DE4-63A4-4071-A8BC-A584F3CD1628

P356

J.JAMCOLLSURG.2008.09.023

P1433

Journal of the American College of Surgeons

P1476

Human polymerized hemoglobin f ...... le: the USA multicenter trial.

@en

P2093

Andrew C Bernard

http://www.w3.org/2001/XMLSchema#string

David B Hoyt

http://www.w3.org/2001/XMLSchema#string

Ernest E Moore

http://www.w3.org/2001/XMLSchema#string

Frederick A Moore

http://www.w3.org/2001/XMLSchema#string

George A Hides

http://www.w3.org/2001/XMLSchema#string

George H Rodman

http://www.w3.org/2001/XMLSchema#string

Gerard J Fulda

http://www.w3.org/2001/XMLSchema#string

Gerardo A Gomez

http://www.w3.org/2001/XMLSchema#string

Laurel A Omert

http://www.w3.org/2001/XMLSchema#string

Leonard J Weireter

http://www.w3.org/2001/XMLSchema#string

P304

1-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JAMCOLLSURG.2008.09.023

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

208

http://www.w3.org/2001/XMLSchema#string

P50

Timothy C Fabian

P577

2008-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24026396

http://www.w3.org/2001/XMLSchema#string

P698

19228496

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial